Birth Control News and Research RSS Feed - Birth Control News and Research

Shire enters into agreement with Sanquin for CINRYZE

Shire enters into agreement with Sanquin for CINRYZE

Shire plc announced today it has entered into an agreement with Sanquin Blood Supply, the manufacturer of CINRYZE (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE. [More]
Women's contraceptive choices often driven by relationships, sexual activity

Women's contraceptive choices often driven by relationships, sexual activity

Women's contraceptive choices are more often driven by current relationships and sexual activity than by long-term pregnancy intentions, according to Penn State College of Medicine researchers. [More]
Survey finds clear unmet need for comprehensive family planning services at health centers

Survey finds clear unmet need for comprehensive family planning services at health centers

As part of a unique survey of nearly 2,000 women of childbearing age who receive health care at the nation's community health centers, 90 percent reported that they were not actively seeking to become pregnant in the next 12 months. Yet more than 3 out of 10 were not using contraceptives at the time of the survey. [More]
Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. [More]
Most patients with depression excluded from antidepressant trials, study finds

Most patients with depression excluded from antidepressant trials, study finds

More than 80 percent of people with depression in the general population aren't eligible for clinical trials of antidepressant drugs, according to a study in the Journal of Psychiatric Practice. [More]
UMass Amherst scientist to study how estrogen-mimicking chemicals in the womb can increase breast cancer risk

UMass Amherst scientist to study how estrogen-mimicking chemicals in the womb can increase breast cancer risk

Much attention has been paid to genetics in breast cancer as disease rates rise, but most women have no family history of the disease, suggesting that there is an environmental risk we don't yet understand, says environmental health scientist Laura Vandenberg in the School of Public Health and Health Sciences at the University of Massachusetts Amherst. [More]
Sociologists to explore ideas, scientific research relating to sexuality at ASA's Annual Meeting

Sociologists to explore ideas, scientific research relating to sexuality at ASA's Annual Meeting

More than 5,500 sociologists will convene in Chicago this August to explore ideas and scientific research relating to sexuality and many other topics, as part of the American Sociological Association's 110th Annual Meeting. This year's theme, "Sexualities in the Social World," shows the importance of research by sociologists in illuminating how social norms and social inequalities affect what sexual behavior is acceptable and who partners with whom. [More]
FDA provides safety update about Essure Birth Control Implant

FDA provides safety update about Essure Birth Control Implant

The FDA first announced their intention to provide a safety update about Essure late yesterday evening. Today's much anticipated report comes on the heals of a private citizen petition that raised serious concerns about the Essure Birth Control Implant and resulted in the launch of an FDA investigation into the birth control device. [More]
Improved birth control advice reduces unintended pregnancy rate among young women

Improved birth control advice reduces unintended pregnancy rate among young women

Providing health workers with training on how to educate young women about intrauterine devices (IUDs) and contraceptive implants reduced the rate of unintended pregnancy by almost half in a study of women seeking family planning services. [More]
ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of TafinlarĀ® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer. [More]
Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures. [More]
Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. [More]
Mayo Clinic provides expert guidance on fertility, conception

Mayo Clinic provides expert guidance on fertility, conception

With Mother's Day being May 10 and May being Women's Health Month, Mayo Clinic offers expert guidance on fertility and conception. [More]
Common diabetes medication causes intersex in fish

Common diabetes medication causes intersex in fish

A medication commonly taken for Type II diabetes, which is being found in freshwater systems worldwide, has been shown to cause intersex in fish -male fish that produce eggs. [More]
Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS). [More]
Study compares cost, benefits, complications of uterine-sparing treatments for fibroids

Study compares cost, benefits, complications of uterine-sparing treatments for fibroids

The relative cost, benefits, and complications of three minimally invasive techniques for reducing or eliminating symptomatic uterine fibroids are being compared in women who don't have cancer and want to preserve their uterus. [More]
Penn State surgeon provides guidelines for diagnosis, management of endometriosis

Penn State surgeon provides guidelines for diagnosis, management of endometriosis

Endometriosis is difficult to diagnose, with women often being told for years that they are experiencing their 'normal period.' According to the Endometriosis Foundation of America, it affects one in ten women. [More]
New book focuses on life events resulting in teen motherhood

New book focuses on life events resulting in teen motherhood

If Diane could reverse time, she never would have slammed the door--an act of teen frustration and ongoing family conflict that finally got her kicked out of her mother's house. [More]
Migraine headaches with auras may increase risk of stroke

Migraine headaches with auras may increase risk of stroke

People who suffer migraine headaches with auras are at roughly double the risk of suffering the most common type of stroke. [More]
Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration. [More]
Advertisement
Advertisement